Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to 10% of a patient’s cfDNA depending on their tumor type and burden. The short half-life of ctDNA ensures that its detection cap...

Full description

Bibliographic Details
Main Authors:	Maria F. Arisi, Efrat Dotan, Sandra V. Fernandez
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	International Journal of Molecular Sciences
Subjects:	circulating tumor DNA cell-free DNA biomarkers minimal residual disease MRD clonal hematopoiesis
Online Access:	https://www.mdpi.com/1422-0067/23/8/4441

Similar Items

Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis
by: Lissa Wullaert, et al.
Published: (2023-10-01)

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses
by: Jan M. van Rees, et al.
Published: (2023-01-01)

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients
by: Daan C. L. Vessies, et al.
Published: (2022-07-01)

Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives
by: Giulia Grizzi, et al.
Published: (2023-05-01)

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
by: Yan Peng, et al.
Published: (2021-11-01)

Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients
by: Huu Thinh Nguyen, et al.
Published: (2022-12-01)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
by: Christian M. Vonk, et al.
Published: (2021-10-01)

Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents
by: Markus G. Seidel, et al.
Published: (2022-08-01)

Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients
by: Huiqin Jiang, et al.
Published: (2023-04-01)

Role of Circulating Tumor DNA in Hematological Malignancy
by: Miho Ogawa, et al.
Published: (2021-04-01)

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer
by: Kezhong Chen, et al.
Published: (2023-07-01)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
by: Eleni Zografos, et al.
Published: (2022-10-01)

Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
by: Hiroki Osumi, et al.
Published: (2020-06-01)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
by: Xiaoxu Fang, et al.
Published: (2022-10-01)

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
by: Lemei Zhu, et al.
Published: (2023-08-01)

Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study
by: Hesong Wang, et al.
Published: (2024-01-01)

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
by: Sakti Chakrabarti, et al.
Published: (2020-09-01)

Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm
by: Oscar D. Pons-Belda, et al.
Published: (2021-11-01)

Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients
by: Hiu Ting Chan, et al.
Published: (2023-01-01)

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
by: Xiaofen Wen, et al.
Published: (2023-10-01)

Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
by: Hiu Ting Chan, et al.
Published: (2020-08-01)

Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
by: Andrew D. Johnston, et al.
Published: (2023-04-01)

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
by: Markus Mayrhofer, et al.
Published: (2018-11-01)

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
by: Misty Dawn Shields, et al.
Published: (2022-08-01)

Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study
by: Zahra Haider, et al.
Published: (2023-06-01)

Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer
by: PAN Ruixin, CHEN Xiaosong, SHEN Kunwei
Published: (2022-09-01)

Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
by: Xianliang Cheng, et al.
Published: (2017-11-01)

Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer
by: Jun Gong, et al.
Published: (2021-09-01)

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients
by: Luc Cabel, et al.
Published: (2019-03-01)

The Prognostic Utility of <i>KRAS</i> Mutations in Tissue and Circulating Tumour DNA in Colorectal Cancer Patients
by: Joel Petit, et al.
Published: (2024-01-01)

Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis
by: LaShanale Wallace, et al.
Published: (2023-10-01)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
by: Sakti Chakrabarti, et al.
Published: (2022-06-01)

Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value
by: Anna Citarella, et al.
Published: (2023-09-01)

RB1 Circulating Tumor DNA in the Blood of Patients with Unilateral Retinoblastoma
by: Jasmine H. Francis, MD, et al.
Published: (2021-09-01)

Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges
by: Hiu Ting Chan, et al.
Published: (2022-07-01)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01)

Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy
by: Hiu Ting Chan, et al.
Published: (2020-08-01)

Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients
by: Evelyn Adusei, et al.
Published: (2021-05-01)

Circulating Tumor DNA in Pediatric Cancer
by: Louise Doculara, et al.
Published: (2022-05-01)

Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review
by: Suzanna J. Schraa, et al.
Published: (2022-04-01)